Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Fujii, Shin Ichiro ^a   Shimizu, Kanako ^a  

^a INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

galactosylceramide; Adjuvant effects; Cross presentation; Dendritic cells; INKT cells

Indexed keywords

B7 ANTIGEN; CD1D ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR GAMMA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; SECONDARY LYMPHOID TISSUE CHEMOKINE; T LYMPHOCYTE RECEPTOR; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER T CELL; NONHUMAN; T LYMPHOCYTE ACTIVATION;

EID: 84886943354     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23432     Document Type: Article

References (10)

1. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; http://dx.doi.org/10.1038/nature06175
2. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-79; http://dx.doi.org/10.1038/nri2569
3. Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 2007; 220:183-98; http:// dx.doi.org/10.1111/j.1600-065X.2007.00561.x
4. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFM-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3:867-74; http://dx.doi.org/10.1038/ni827
5. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of alphagalactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182:2492-501; http://dx.doi.org/10.4049/jimmunol.0800126
6. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 2007; 178:2853-61.
7. Fujii S. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol 2008; 29:242-9; http:// dx.doi.org/10.1016/j.it.2008.02.002
8. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171:5140-7.
9. Fujii S, Goto A, Shimizu K. Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity. Blood 2009; 113:4262-72; http://dx.doi.org/10.1182/ blood-2008-08-176446
10. Shimizu K, Mizuno T, Shinga J, Asakura M, Kakimi K, Ishii Y, et al. Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells. Cancer Res 2013; 73:62-73; http://dx.doi. org/10.1158/0008-5472.CAN-12-0759